[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 63, "title": "CEO & Vice Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 994800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Shin J.D., M.B.A.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 406256, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan E. Anderman J.D.", "title": "Senior VP, General Counsel & Corporate Secretary", "fiscalYear": 2024, "totalPay": 541620, "exercisedValue": 0, "unexercisedValue": 6250}, {"maxAge": 1, "name": "Ms. Vered  Bisker-Leib MBA, Ph.D.", "age": 53, "title": "Advisor", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 1531657, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Neil L. Lerner CPA", "age": 57, "title": "Senior VP & Chief Accounting Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Minori  Rosales M.D., Ph.D.", "age": 61, "title": "Senior VP & Head of Clinical Development", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "Senior VP & Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.38, "open": 2.44, "dayLow": 2.29, "dayHigh": 2.44, "regularMarketPreviousClose": 2.38, "regularMarketOpen": 2.44, "regularMarketDayLow": 2.29, "regularMarketDayHigh": 2.44, "payoutRatio": 0.0, "beta": 1.217, "forwardPE": -4.7058825, "volume": 1223657, "regularMarketVolume": 1223657, "averageVolume": 1446470, "averageVolume10days": 948030, "averageDailyVolume10Day": 948030, "bid": 2.36, "ask": 2.4, "bidSize": 5, "askSize": 8, "marketCap": 331876800, "fiftyTwoWeekLow": 0.765, "fiftyTwoWeekHigh": 4.08, "priceToSalesTrailing12Months": 390.4433, "fiftyDayAverage": 2.0417, "twoHundredDayAverage": 2.054225, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 225624000, "profitMargins": 0.0, "floatShares": 88910115, "sharesOutstanding": 138282000, "sharesShort": 7432323, "sharesShortPriorMonth": 7629122, "sharesShortPreviousMonthDate": 1745971200, "dateShortInterest": 1748563200, "sharesPercentSharesOut": 0.0537, "heldPercentInsiders": 0.14163, "heldPercentInstitutions": 0.70018995, "shortRatio": 9.58, "shortPercentOfFloat": 0.1019, "impliedSharesOutstanding": 138282000, "bookValue": 0.797, "priceToBook": 3.0112925, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -55221000, "trailingEps": -0.4, "forwardEps": -0.51, "enterpriseToRevenue": 265.44, "enterpriseToEbitda": -3.684, "52WeekChange": 1.1621621, "SandP52WeekChange": 0.09544468, "quoteType": "EQUITY", "currentPrice": 2.4, "targetHighPrice": 32.0, "targetLowPrice": 6.0, "targetMeanPrice": 13.22222, "targetMedianPrice": 10.0, "recommendationMean": 1.22222, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 112635000, "totalCashPerShare": 0.815, "ebitda": -61246000, "totalDebt": 6381000, "quickRatio": 7.559, "currentRatio": 8.332, "totalRevenue": 850000, "debtToEquity": 5.786, "revenuePerShare": 0.006, "returnOnAssets": -0.26411, "returnOnEquity": -0.41312, "grossProfits": 850000, "freeCashflow": -25007124, "operatingCashflow": -44175000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -72.73059, "financialCurrency": "USD", "symbol": "CMPX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1617629400000, "postMarketChangePercent": 1.66666, "regularMarketChangePercent": 0.840335, "regularMarketPrice": 2.4, "marketState": "CLOSED", "postMarketPrice": 2.44, "postMarketChange": 0.04, "regularMarketChange": 0.02, "regularMarketDayRange": "2.29 - 2.44", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1446470, "fiftyTwoWeekLowChange": 1.6350001, "fiftyTwoWeekLowChangePercent": 2.1372552, "fiftyTwoWeekRange": "0.765 - 4.08", "fiftyTwoWeekHighChange": -1.6799998, "fiftyTwoWeekHighChangePercent": -0.41176468, "fiftyTwoWeekChangePercent": 116.21621, "earningsTimestamp": 1746705601, "earningsTimestampStart": 1754915400, "earningsTimestampEnd": 1755261000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.4, "epsForward": -0.51, "epsCurrentYear": -0.48167, "priceEpsCurrentYear": -4.9826646, "fiftyDayAverageChange": 0.3583002, "fiftyDayAverageChangePercent": 0.17549112, "twoHundredDayAverageChange": 0.34577513, "twoHundredDayAverageChangePercent": 0.16832389, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-11-02", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1750454686, "regularMarketTime": 1750449602, "exchange": "NCM", "messageBoardId": "finmb_266166780", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "displayName": "Compass Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-06-21"}]